About Marksans Pharma Limited

Marksans Pharma Limited is a globally focused, customer-centric pharmaceutical formulations company specialising in over-the-counter (OTC) and prescription (Rx) products, with a strong presence across regulated markets including the US, UK/Europe, Australia/New Zealand, and Rest of the World (RoW). Established originally within Glenmark in 2001 and later spun off as Glenmark Laboratories before being renamed Marksans Pharma Limited, the Company has scaled through organic capacity expansion and strategic acquisitions such as Time-Cap Laboratories (US, 2015), Relonchem (UK, 2008), Bell, Sons & Co. (UK, 2013), Nova Pharmaceuticals (Australia, 2005), Access Healthcare (UAE, 2022), and a Goa facility acquired from Tevapharm India (2022) to bolster liquids and topical capacity. It operates four manufacturing units (Goa—two sites, Southport UK, Farmingdale USA) and four R&D centres (Goa, Navi Mumbai, Southport, Farmingdale), with installed capacity of 26 billion units per annum across tablets, capsules, bottles, sachets, tubes, ointments, liquids, and creams, serving over 50 countries with cGMP-compliant facilities accredited by USFDA, UK MHRA, TGA, EMA, and Health Canada. Core therapeutic areas span pain management, upper respiratory, digestive health, cardiovascular, CNS, anti-diabetics, antibiotics, oncology, skin care, and VMS, supported by over 300 products, 1,500 SKUs, 25 approved ANDAs/MAs, 100 products in pipeline, and an innovation plan targeting 12–13 launches annually. For FY 2024–25, operating revenue was Rs 2,622.80 crore with EBITDA Rs 528.64 crore and PAT Rs 382.62 crore, reflecting best-ever performance; the Company highlights a debt-free, cash-positive position with ROE 16.7 and ROCE 21.5, anchored by strong US growth and expansion of OTC. Geographic operations are anchored by subsidiaries: Time-Cap Laboratories Inc. (US), Bell, Sons & Co. Druggists Ltd. and Relonchem Ltd. (UK), Nova Pharmaceuticals Australasia Pty Ltd (Australia), and Access Healthcare (UAE), with distribution relationships spanning Walmart, Walgreens, CVS, Dollar General, Target, Kroger in the US and major UK retail/wholesale partners including NHS-linked channels.

Marksans Pharma Business segments

• Revenue split by segment/vertical (FY 2024–25):
  • OTC — 78.8%

  • Rx — 21.2%

• Geographic split (FY 2024–25):
  • India — Rs 0.00 crore (0.0%) [Not disclosed in geography chart; India shown as manufacturing base, not a reported revenue bucket]

  • International — Rs 2,622.80 crore (100.0%) [Sum of disclosed geographies equals consolidated revenue; regional details below]

  • Within international:
    • US & North America — Rs 1,236.60 crore (47.2%)

    • UK & Europe — Rs 1,029.80 crore (39.3%)

    • Australia & New Zealand — Rs 252.80 crore (9.6%)

    • RoW — Rs 104.00 crore (4.0%)

  • USA within international — Rs 1,236.60 crore (47.2%) [explicit US figure presented within US & North America bucket]

Marksans Pharma Key Management

• Mark Saldanha — Chairman & Managing Director

• Sandra Saldanha — Whole-time Director

• Varddhman V. Jain — Whole-time Director

• David Mohammed — Managing Director – Australia Operations

• Sathish Kumar — Managing Director – UK Operations

• Anjani Kumar — COO – US Operations

• Jitendra Sharma — Group Chief Financial Officer

• Harshavardhan Panigrahi — Company Secretary

Latest Updates on Marksans Pharma

• Achieved record operating revenue of Rs 2,622.80 crore in FY 2024–25 with EBITDA Rs 528.64 crore and PAT Rs 382.62 crore; EBITDA margin 20.2% and continued debt-free, cash-positive status over five years.

• OTC business crossed Rs 2,000 crore milestone, driven by deeper store-brand penetration and retailer partnerships across North America; US market revenue grew ~35% YoY to Rs 1,236.60 crore on new launches and share gains.

• Commenced commercial shipments from the acquired Goa facility (Tevapharm India) to the US and UK; roadmap to scale utilisation from ~25% towards 50–85% over two years to unlock operating leverage.

• Expanded total capacity to 26 billion units per annum; targeted ramp-up at Goa site expected to enable up to 8 billion units annually across tablets, capsules, ointments, liquids, and creams.

• Strengthened pipeline to 100+ products with highest-ever filings; US pipeline at 79 products, and UK/Europe recorded 18 filings and 12 approvals during the year; Australia filed 3 with 3 approvals.

• Set aspiration to reach Rs 3,000 crore revenue in FY 2025–26 and double US OTC revenue, while moving from top-5 to top-3 Indian pharma in the UK by revenue, funded via internal accruals.